These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evolving role of calcium channel blockers in heart failure. Pieper JA. Pharmacotherapy; 1996 Oct; 16(2 Pt 2):43S-49S. PubMed ID: 8668605 [Abstract] [Full Text] [Related]
3. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. Costanzo P, Perrone-Filardi P, Petretta M, Marciano C, Vassallo E, Gargiulo P, Paolillo S, Petretta A, Chiariello M. J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836 [Abstract] [Full Text] [Related]
4. Ca2+ channel subtypes and pharmacology in the kidney. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Circ Res; 2007 Feb 16; 100(3):342-53. PubMed ID: 17307972 [Abstract] [Full Text] [Related]
12. Calcium channel blockers and coronary heart disease. Inzitari M, Di Bari M, Marchionni N. Aging Clin Exp Res; 2005 Aug 16; 17(4 Suppl):6-15. PubMed ID: 16640169 [Abstract] [Full Text] [Related]
14. Revival of nifedipine, a dihydropyridine-based calcium blocker. Yamagishi S, Nakamura K. Med Hypotheses; 2007 Aug 16; 68(3):565-7. PubMed ID: 17011717 [Abstract] [Full Text] [Related]
15. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Toba H, Nakagawa Y, Miki S, Shimizu T, Yoshimura A, Inoue R, Asayama J, Kobara M, Nakata T. Hypertens Res; 2005 Aug 16; 28(8):689-700. PubMed ID: 16392774 [Abstract] [Full Text] [Related]
16. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K. Hypertens Res; 2009 Jul 16; 32(7):575-80. PubMed ID: 19444280 [Abstract] [Full Text] [Related]
18. [Calcium antagonists: current and future applications based on new evidence. Pleiotropic effects of calcium channel blockers on vascular endothelial function]. Morimoto Y, Kureishi-Bando Y, Murohara T. Clin Calcium; 2010 Jan 16; 20(1):69-75. PubMed ID: 20048436 [Abstract] [Full Text] [Related]